Key result
Chlorogenic acid mitigates doxorubicin cardiotoxicity, halving cardiomyocyte death to ~6% while enhancing tumor killing.
Why the study?
Doxorubicin remains the standard of care for osteosarcoma despite resistance mechanisms and adverse reactions, and few studies have evaluated chlorogenic acid as a combination partner to overcome these limitations.
Does concomitant chlorogenic acid enhance the cytotoxic efficacy of doxorubicin in human osteosarcoma cells while attenuating doxorubicin-induced cytotoxicity in H9c2 cardiomyocytes?
Does concomitant chlorogenic acid enhance the cytotoxic efficacy of doxorubicin in human osteosarcoma cells while attenuating doxorubicin-induced cytotoxicity in H9c2 cardiomyocytes?
This preclinical study demonstrates that chlorogenic acid acts simultaneously as a chemosensitizer in human osteosarcoma cells and as a cardioprotective agent against doxorubicin-induced cytotoxicity in rat H9c2 cardiomyocytes.
Answers are grounded in this paper and cite their sources.
Does not support clinical use with doxorubicin; leaves open dual chemosensitizing-cardioprotective effects pending in vivo and human trials.
Despite the recurring outbreak of resistance mechanisms and adverse reactions, doxorubicin (Doxo) still remains the standard-of-care for several cancers, including osteosarcoma (OS). As an appealing source of phytochemical compounds, naturally occurring molecules have extensively been reported to overcome Doxo limitations in preclinical models. Unlike other dietary polyphenols, only few studies recognize chlorogenic acid (CGA) as a potential partner in combination therapy, while, conversely, its anticancer evidence is steadily growing, ultimately in OS. On this basis, herein we examine the cooperating effects between CGA and Doxo in U2OS and MG-63 human OS cells. With respect to Doxo alone, the concomitant administration of CGA further decreased cell viability and growth, promoting cell death potentially via apoptosis induction. Furthermore, a longer-lasting reduction in clonogenic potential deeply supported the CGA ability to improve Doxo efficacy in those cells. Remarkably, CGA treatment ameliorated Doxo-induced cytotoxicity in H9c2 rat cardiomyocyte cells instead. Although inactivation of p44/42 MAPK was detected in response to CGA plus Doxo, PD98059-mediated p44/42 MAPK impairment enhanced the combination outcome in OS cells. These findings firstly propose CGA as a promising chemosensitizer and cardioprotective agent in OS therapy, suggesting the p44/42 MAPK pathway as relevantly involved in CGA-mediated Doxo susceptibility.
No takes yet. Share an insight, caveat, or question.
Salzillo et al. (2021) studied Osteosarcoma and doxorubicin-induced cardiotoxicity (in vitro cell models). Chlorogenic acid (CGA) plus doxorubicin (Doxo) vs. Doxorubicin alone, chlorogenic acid alone, or vehicle control (ethanol/DMSO) was evaluated on Cell viability, cell growth, and propidium iodide (PI)-positive cell death (p=<0.05). Chlorogenic acid combined with doxorubicin increased osteosarcoma cell death from 8.16% to 14.86% in U2OS cells while reducing cardiomyocyte death from 12.65% to 6.08% in H9c2 cells.
Synapse has enriched 10 related papers. Consider them for comparative context: